| Patient | Lorraine Hansberry |
|---|---|
| Date of birth | 1993-05-19 |
| Identifiers | MRN HR-ML034-SYN; SSN (made up) 000-34-7158 |
| Document date | 2026-06-29 |
| Author | Odette Marchetti-Fields, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review on day 1 of cycle 4 of modified FOLFIRINOX. [S]
Ms. Hansberry returns on the first day of her fourth cycle; cycles 1 to 3 were given on schedule. After each cycle she has nausea for a day or two, controlled with olanzapine at night, and two or three loose stools on days 3 to 5, settled with loperamide. For a few days after each cycle cold drinks hurt her throat and her fingers and toes tingle in the cold, and the fingertips now tingle mildly between cycles; she can still type and do buttons. Pain is 2 out of 10 with one or two oxycodone tablets a day, and she sleeps through. She writes three mornings a week. Her stools are formed with pancrelipase and her weight is steady. Home fasting glucose readings are 110 to 130 mg/dL. She has had no bleeding or black stools since the iron. The germline panel and the tumor profile have both resulted. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Treatment | Cycles 1 to 3 on schedule; cycle 4 today |
| Effects | Nausea one or two days; loose stools days 3 to 5; cold-induced tingling, now mild between cycles |
| Genetic results | Germline panel negative; tumor KRAS G12D, TP53 and CDKN2A alterations, microsatellite stable, no BRCA1, BRCA2 or PALB2 variant, no NTRK, NRG1 or ALK fusion |
| Pain | 2 out of 10 on oxycodone once or twice a day |
| Writing | Three mornings a week |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired for three days after each cycle; weight 54.8 kg; no fever |
| Gastrointestinal | Positive | Nausea one or two days per cycle; loose stools days 3 to 5; no black stools |
| Neurological | Positive | Cold-induced tingling after each cycle; mild fingertip tingling between cycles; no weakness |
| Hematologic and lymphatic | Negative | No bleeding or bruising |
| Cardiovascular | Negative | No leg swelling or calf pain |
| Psychiatric | Positive | Worried before each scan and test; PHQ-9 8, GAD-7 9; no thoughts of self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Pantoprazole 40 mg delayed-release oral tablet, one tablet by mouth once daily before breakfast | One tablet daily before breakfast | Oral route | 2026-04-20 | active | S |
| Ferric carboxymaltose 50 mg/mL injection, 750 mg intravenously, two doses one week apart | 750 mg intravenously; two doses one week apart | Intravenous route | 2026-04-24 to 2026-05-01 | completed | S |
| Oxycodone 5 mg oral tablet, one tablet by mouth every 4 hours as needed for pain | One tablet every 4 hours as needed | Oral route | 2026-05-04 | active | S |
| Senna 8.6 mg oral tablet, two tablets by mouth at night while taking oxycodone | Two tablets at night | Oral route | 2026-05-04 | active | S |
| Pancrelipase delayed-release capsule (lipase 36,000 units), two capsules with each meal and one with each snack | Two capsules with each meal, one with each snack | Oral route | 2026-05-04 to 2026-10-05 | completed | S |
| Oxaliplatin 5 mg/mL injection, 135 mg (85 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cycles | Day 1 every 14 days for six cycles | Intravenous route | 2026-05-18 to 2026-07-27 | completed | S |
| Irinotecan 20 mg/mL injection, 238 mg (150 mg/m2) intravenously over 90 minutes on day 1 of each 14-day cycle, cycles 1 to 5 | Day 1 every 14 days, cycles 1 to 5 | Intravenous route | 2026-05-18 to 2026-07-13 | completed | S |
| Leucovorin 10 mg/mL injection, 634 mg (400 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cycles | Day 1 every 14 days for six cycles | Intravenous route | 2026-05-18 to 2026-07-27 | completed | S |
| Fluorouracil 50 mg/mL injection, 3800 mg (2400 mg/m2) by continuous infusion over 46 hours through the port from day 1 of each 14-day cycle, for six cycles, with no bolus | 46-hour infusion from day 1 every 14 days for six cycles | Intravenous route | 2026-05-18 to 2026-07-29 | completed | S |
| Pegfilgrastim 6 mg/0.6 mL prefilled syringe, 6 mg under the skin on day 3 of each cycle, after the pump is disconnected | 6 mg on day 3 of each cycle | Subcutaneous route | 2026-05-20 to 2026-07-29 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea | One tablet every 8 hours as needed | Oral route | 2026-05-18 | active | S |
| Olanzapine 5 mg oral tablet, one tablet by mouth at night on days 1 to 4 of each cycle | One tablet at night on days 1 to 4 | Oral route | 2026-05-18 | active | S |
| Loperamide 2 mg oral capsule, two capsules at the first loose stool, then one after each loose stool, no more than eight a day unless directed | 4 mg at onset, then 2 mg after each loose stool | Oral route | 2026-05-18 | active | S |
| Apixaban 2.5 mg oral tablet, one tablet by mouth twice daily during chemotherapy, stopped three days before surgery | One tablet twice daily | Oral route | 2026-06-29 to 2026-08-21 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-29 | Body height | 163 | cm | S |
| 2026-06-29 | Body weight | 54.8 | kg | S |
| 2026-06-29 | Body mass index (BMI) [Ratio] | 20.6 | kg/m2 | S |
| 2026-06-29 | Systolic blood pressure | 110 | mm[Hg] | S |
| 2026-06-29 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-06-29 | Heart rate | 84 | /min | S |
| 2026-06-29 | Respiratory rate | 16 | /min | S |
| 2026-06-29 | Body temperature | 36.6 | Cel | S |
| 2026-06-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-29 | Hemoglobin [Mass/volume] in Blood | 11.2 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-06-29 | Leukocytes [#/volume] in Blood by Automated count | 8.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-06-29 | Neutrophils [#/volume] in Blood by Automated count | 5.8 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-06-29 | Platelets [#/volume] in Blood by Automated count | 214 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-06-29 | Creatinine [Mass/volume] in Serum or Plasma | 0.72 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-06-29 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 114 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-06-29 | Glucose [Mass/volume] in Serum or Plasma | 128 | mg/dL | 70-99 mg/dL | High | S |
| 2026-06-29 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 7-35 U/L | Normal | S |
| 2026-06-29 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 8-35 U/L | Normal | S |
| 2026-06-29 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 120 | U/L | 35-104 U/L | High | S |
| 2026-06-29 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-06-29 | Albumin [Mass/volume] in Serum or Plasma | 3.5 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-06-29 | Magnesium [Mass/volume] in Serum or Plasma | 1.9 | mg/dL | 1.7-2.2 mg/dL | Normal | S |
| 2026-06-29 | Ferritin [Mass/volume] in Serum or Plasma | 88 | ng/mL | 15-150 ng/mL | Normal | S |
| 2026-06-29 | Cancer Ag 19-9 [Units/volume] in Serum or Plasma | 210 | U/mL | <=35 U/mL | High | S |
| 2026-06-29 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 2026-06-29 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 9 | {score} | S | ||
| 2026-06-29 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 2 | {score} | S |
Vital signs recorded on 2026-06-29; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 54.8 kg; blood pressure 110/70, pulse 84 |
| Eyes | No icterus |
| Abdomen | Mild epigastric tenderness; port site clean |
| Neurological | Light touch slightly reduced at the fingertips; vibration sense and reflexes normal; fine finger movements normal (grade 1 sensory neuropathy) |
| Extremities | No leg swelling |
| Psychiatric | Engaged, dry humor, organized |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Epigastric pain for about two months, boring through to the back and worse after meals and lying flat, with nausea, early fullness, a loss of 5 kg (8 percent of her weight), and pale, loose stools: an upper abdominal cause such as a bleeding ulcer or a pancreatic or duodenal tumor must be found. Upper endoscopy and pancreas-protocol CT booked this week | resolved | confirmed | R10.13 | S — Synthetic presenting problem anchored to the documented collapse in pain and the account of a suspected duodenal ulcer. Superseded by the diagnosis at the second visit. |
| Iron deficiency anemia from chronic upper gastrointestinal blood loss: black stools on and off for three weeks, two near-fainting spells, hemoglobin 9.1 g/dL, MCV 74 fL, ferritin 6 ng/mL | active | confirmed | D50.0 | S — Synthetic finding anchored to the documented account that she was told she had anemia and bleeding ulcers. |
| New hyperglycemia: A1c 6.6% and random glucose 132 mg/dL in a lean woman of 32 who is losing weight; new diabetes with weight loss can be the first sign of a pancreatic cancer, so it is to be confirmed and explained, not labeled type 2 | resolved | confirmed | R73.09 | S — Synthetic finding; superseded when diabetes due to the pancreatic cancer was recorded at the second visit. |
| Adenocarcinoma of the head of the pancreas, 3.1 cm, invading the duodenum, borderline resectable (tumor contact of more than half the circumference of the superior mesenteric vein, no arterial contact), no distant spread, CA 19-9 486 U/mL after biliary drainage; on EUS-guided biopsy; synthetic modern detail linked to her documented cancer, whose primary site the sources record differently | active | confirmed | C25.0 | S — Synthetic histology, site, stage and course; the sources say she died of cancer and differ on whether it was pancreatic, duodenal, or colonic with spread to the pancreas (R). See sources.md. |
| Diabetes due to the pancreatic cancer (pancreatogenic, type 3c): A1c 6.6% at intake and fasting glucose 141 mg/dL | active | confirmed | E08.9 | S — Synthetic consequence of the synthetic tumor. |
| Exocrine pancreatic insufficiency from obstruction of the pancreatic duct: pale, floating, loose stools after fatty meals and weight loss | active | confirmed | K86.81 | S — Synthetic consequence of the synthetic tumor; diagnosed clinically, as guidance allows in pancreatic cancer. |
| Cancer-related pain in the upper abdomen and back, 6 out of 10, with sleep broken by it | active | confirmed | G89.3 | S — Synthetic symptom of the synthetic tumor. |
| Obstruction of the distal common bile duct by the tumor, relieved by a covered metal stent placed at ERCP | active | confirmed | K83.1 | S — Synthetic consequence of the synthetic tumor. |
| Oxaliplatin peripheral neuropathy, grade 1: tingling in the fingers and toes in the cold, lasting a few days after each cycle, with mild tingling at the fingertips between cycles; no effect on writing or buttons | active | confirmed | G62.0 | S — Synthetic common effect of oxaliplatin. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count with neutrophils and platelets | Before each chemotherapy cycle and at each visit | Completed today | Hemoglobin 11.2 g/dL, white cells 8.9, neutrophils 5.8, platelets 214; full dose |
| Laboratory | Kidney and liver function, albumin | Before each cycle | Completed today | Creatinine 0.72 mg/dL, eGFR 114; ALT 26, AST 27, alkaline phosphatase 120 U/L, bilirubin 0.6 mg/dL; albumin 3.5 g/dL |
| Laboratory | Magnesium | Before each cycle | Completed today | 1.9 mg/dL |
| Laboratory | Ferritin after intravenous iron | Four to eight weeks after the last dose | Completed today | 88 ng/mL |
| Laboratory | CA 19-9 | At diagnosis after biliary drainage, every two cycles during treatment, before surgery, after surgery, then every three to six months | Completed today | 210 U/mL, from 486 at diagnosis |
| Imaging | Interim restaging CT | Every two months during chemotherapy before surgery | Ordered | Ordered today for two weeks from now, before cycle 5 |
| Laboratory | Germline multigene panel | Once, at diagnosis | Up to date | Negative for pathogenic variants; reviewed with the genetic counselor; no cascade testing needed |
| Laboratory | Tumor molecular profiling | At diagnosis | Up to date | KRAS G12D, TP53 and CDKN2A alterations; microsatellite stable; no BRCA1, BRCA2 or PALB2 variant; no NTRK, NRG1 or ALK fusion |
| Laboratory | Hepatitis B, hepatitis C and HIV screening | Before chemotherapy | Up to date | Negative before cycle 1; hepatitis B surface antibody negative, so vaccination after chemotherapy |
| Examination | Oxaliplatin neuropathy: symptoms and examination | Before each oxaliplatin dose | Completed today | Grade 1 sensory neuropathy; full dose continues |
| Medication safety | Nausea, vomiting and diarrhea control | Each cycle | Completed today | Nausea one or two days on olanzapine; loose stools controlled with loperamide |
| Medication safety | Venous thromboembolism prophylaxis | During chemotherapy | Completed today | No bleeding for eight weeks and hemoglobin 11.2 g/dL: apixaban 2.5 mg twice daily started today, with teaching on bleeding signs |
| Survey | Pain score and opioid review | Each visit | Completed today | Pain 2 out of 10 |
| Self-management | Weight, nutrition and enzyme replacement | Each visit | Completed today | Weight 54.8 kg, 1 percent below the weight at diagnosis; stools formed on pancrelipase |
| Laboratory | Glucose and home readings | Each visit and before each cycle | Completed today | Glucose 128 mg/dL; home fasting 110 to 130 |
| Examination | Dilated eye examination and urine albumin-to-creatinine ratio | At diagnosis of diabetes, then yearly | Deferred | A deviation: the dilated eye examination and urine albumin-to-creatinine ratio planned when diabetes was diagnosed were not arranged, amid staging and the start of chemotherapy. Harm is unlikely after two months of mild diabetes, but the check is a standard of care. Corrective action: both booked with the visit after surgery, when treatment visits are fewer |
| Survey | Distress and depression screen (PHQ-9, GAD-7) | At diagnosis, at each treatment phase, and when symptoms change | Completed today | PHQ-9 8 and GAD-7 9; worry before scans; she sees the palliative care social worker monthly |
Goal progress:
Immunizations given today: Recombinant zoster vaccine, dose 2 of 2 [S]
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026); Khorana AA, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(21):2541-2556 (PMID 27247221) (2016); Stoffel EM, et al. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol 2019;37(2):153-164 (PMID 30457921) (2019); Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023); Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020;38(24):2782-2797 (PMID 32658626) (2020); Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (PMID 32663120) (2020); American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2026 (classification of diabetes, including diabetes of the exocrine pancreas) (2026); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Interim CT in two weeks. Cycles 5 and 6 every two weeks. Restaging CT and review after cycle 6. Call at once for fever of 38.0 °C or more, diarrhea not controlled by loperamide, bleeding, or yellow eyes. Next scheduled visit 2026-08-10: after six cycles: restaging CT and CA 19-9, decision for surgery, and preparation for pancreaticoduodenectomy. [S]